Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model

被引：4

作者：

Noort, Willy A. ^{[1
]}

Groen, Richard W. J. ^{[1
]}

Raymakers, Reinier ^{[1
]}

Aalders, Linda ^{[1
]}

Hofhuis, Frans M. ^{[1
]}

Van Kessel, Berris ^{[1
]}

Van Velzen, Jeroen F. ^{[1
]}

de Bruijn, Joost ^{[2
]}

Yuan, Huipin ^{[3
]}

van Bueren, Jeroen Lammerts ^{[4
]}

Bloem, Andries C. ^{[1
]}

Parren, Paul W. H. I. ^{[4
]}

Lokhorst, Henk ^{[1
]}

Mutis, Tuna ^{[1
]}

Martens, Anton C. M. ^{[1
]}

机构：

[1] UMC Utrecht, Utrecht, Netherlands

[2] Xpand Biotechnol, Bilthoven, Netherlands

[3] Xpand Biotechnol BV, Bilthoven, Netherlands

[4] Genmab BV, Utrecht, Netherlands

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.940.940

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

940

引用

页数：2

共 41 条

[21] miR-26a as a novel potential therapeutic via inhibit CD38 translation and may overcome datatumumab resistance in multiple myeloma(MM)
Zhao, Jianjun
Hu, Yi
Liu, Huimin
Fang, Chuanfeng
Li, Chen
Xhyliu, Fjorela
Bodo, Juraj
Dysert, Hayley
Habermehl, Gabriel
Russell, Benjamin
Li, Wenjun
Chappell, Marcia
Jiang, Xiaofeng
Ondrejka, Sarah
Hsi, Eric
Maciejewski, Jaroslaw P.
Yi, Qing
Anderson, Kenneth C.
Munshi, Nikhil C.
Ao, Geyou
Valent, Jason
Lin, Jianhong
JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
[22] MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells
Xing, Lijie
Li, Yuyin
Lin, Liang
Yu, Tengteng
Wen, Kenneth
Cho, Shih-Feng
Hsieh, Phillip A.
Kinneer, Krista
Munshi, Nikhil C.
Anderson, Kenneth C.
Tai, Yu-Tzu
BLOOD, 2019, 134
[23] Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
Estefanía García-Guerrero
Ralph Götz
Sören Doose
Markus Sauer
Alfonso Rodríguez-Gil
Thomas Nerreter
K. Martin Kortüm
José A. Pérez-Simón
Hermann Einsele
Michael Hudecek
Sophia Danhof
Leukemia, 2022, 36 : 297 - 297
[24] Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Kazandjian, Dickran
Quach, Hang
Sia, Hanlon
Ho, Phoebe Joy
Spencer, Andrew
Schroeder, Mark A.
Dhakal, Binod
Cochrane, Tara
Zonder, Jeffrey A.
Yi, Nancy
Duchesne, Dominique
Shah, Tejas
Garton, Andrew
Menon, Vinu
Gn, Sunitha
Sammicheli, Stefano
Zhukovsky, Eugene
Konto, Cyril
Pacaud, Lida
Tan, Peter
BLOOD, 2023, 142
[25] VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Yu, Tengteng
Chaganty, Bharat
Lin, Liang
Xing, Lijie
Ramakrishnan, Boopathy
Wen, Kenneth
Hsieh, Phillip A.
Wollacott, Andrew
Viswanathan, Karthik
Adari, Hedy
Cho, Shih-Feng
Li, Yuyin
Chen, Hailin
Yang, Wenjuan
Xu, Yan
An, Gang
Qiu, Lugui
Munshi, Nikhil
Babcock, Gregory
Shriver, Zachary
Myette, James R.
Anderson, Kenneth C.
Tai, Yu-Tzu
BLOOD CANCER JOURNAL, 2020, 10 (11)
[26] VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo
Tengteng Yu
Bharat Chaganty
Liang Lin
Lijie Xing
Boopathy Ramakrishnan
Kenneth Wen
Phillip A. Hsieh
Andrew Wollacott
Karthik Viswanathan
Hedy Adari
Shih-Feng Cho
Yuyin Li
Hailin Chen
Wenjuan Yang
Yan Xu
Gang An
Lugui Qiu
Nikhil Munshi
Gregory Babcock
Zachary Shriver
James R. Myette
Kenneth C. Anderson
Yu-Tzu Tai
Blood Cancer Journal, 10
[27] A chimeric humanized anti-CD40 antibody renders human multiple myeloma (MM) cells refractory to the mitogenic and protective effects of IL-6
Tai, YT
Mitsiades, CS
Catley, LP
Burger, R
Podar, K
Shringarpure, R
Hideshima, T
Chauhan, D
Hamasaki, M
Ishitsuka, K
Richardson, P
Munshi, N
Treon, S
Anderson, K
BLOOD, 2003, 102 (11) : 935A - 935A
[28] SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial
Tian, Ying
Zhou, Keshu
Lin, Quande
Qian, Wenbin
Yang, Wei
Sao, Li
Yuan, Guolin
Yan, Xiaojing
Ma, Liangming
Zhou, Xin
Liu, Lihong
Zhu, Fangbing
Zuo, Xuelan
Du, Xin
Ji, Xu
Zhang, Xuzhao
Shen, Jing
Zhou, Hai
Li, Na
Chen, Wenming
BLOOD, 2024, 144 : 4746 - 4747
[29] Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab (vol 35, pg 201, 2021)
Garcia-Guerrero, Estefania
Gotz, Ralph
Doose, Soren
Sauer, Markus
Rodriguez-Gil, Alfonso
Nerreter, Thomas
Kortum, K. Martin
Perez-Simon, Jose A.
Einsele, Hermann
Hudecek, Michael
Danhof, Sophia
LEUKEMIA, 2022, 36 (01) : 297 - 297
[30] Low levels of circulating CS1, a newly identified multiple myeloma (MM) antigen for a novel humanized HuLuc63 monoclonal antibody, is detected in MM patient sera and correlates with active disease
Tai, Yu-Tzu
Rice, Audie G.
Leiba, Marav
Li, Xian-Feng
Burger, Peter
Song, Weihua
Prabhala, Rao
Dillon, Myles
Tolan, Edie
Xie, Xanling
Hideshima, Teru
Raje, Noopur
Richardson, Paul
Munshi, Nihkil C.
Nagler, Arnon
Loiseau, Herve Avet
Afar, Daniel E. H.
Anderson, Kenneth C.
BLOOD, 2007, 110 (11) : 452A - 452A

← 1 2 3 4 5 →